Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Express Scripts
Colorcon
Baxter
AstraZeneca

Last Updated: May 28, 2022

Duchesnay Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Duchesnay
International Patents:136
US Patents:12
Tradenames:3
Ingredients:2
NDAs:3

Drugs and US Patents for Duchesnay

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes 9,566,252 See Plans and Pricing See Plans and Pricing
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes 6,245,819 See Plans and Pricing See Plans and Pricing
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes 9,855,224 See Plans and Pricing See Plans and Pricing
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes 8,772,353 See Plans and Pricing See Plans and Pricing
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 AB RX Yes Yes 9,937,132 See Plans and Pricing Y See Plans and Pricing
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes 8,236,861 See Plans and Pricing See Plans and Pricing
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes 9,241,915 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Duchesnay

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 7,560,122 See Plans and Pricing
Duchesnay DICLEGIS doxylamine succinate; pyridoxine hydrochloride TABLET, DELAYED RELEASE;ORAL 021876-001 Apr 8, 2013 6,340,695 See Plans and Pricing
Duchesnay DICLEGIS doxylamine succinate; pyridoxine hydrochloride TABLET, DELAYED RELEASE;ORAL 021876-001 Apr 8, 2013 7,560,122 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for DUCHESNAY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 20 mg/20 mg ➤ Subscribe 2018-08-28
➤ Subscribe Delayed-release Tablets 10 mg/10 mg ➤ Subscribe 2013-08-01

International Patents for Duchesnay Drugs

Country Patent Number Estimated Expiration
Hong Kong 1197035 See Plans and Pricing
Japan 2017525731 See Plans and Pricing
Mexico 355912 See Plans and Pricing
Czech Republic 299439 See Plans and Pricing
Estonia 05344 See Plans and Pricing
Austria 387910 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2005077350 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Duchesnay Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1713458 PA2015023,C1713458 Lithuania See Plans and Pricing PRODUCT NAME: OSPEMIFENAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/978/001, 2015 01 15 EU/1/14/978/002 20150115
1713458 SPC/GB15/035 United Kingdom See Plans and Pricing PRODUCT NAME: OSPEMIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/14/978/001 20150115; UK EU/1/14/978/002 20150115
1713458 CR 2015 00031 Denmark See Plans and Pricing PRODUCT NAME: OSPEMIFENE OR A GEOMETRIC ISOMER THEREOF, A STEREOISOMER THEREOF, A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AN ESTER THEREOF OR A METABOLITE THEREOF; REG. NO/DATE: EU/1/14/978/001-002 20150115
1713458 132016000023047 Italy See Plans and Pricing PRODUCT NAME: OSPEMIFENE IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(SENSHIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/978/001-002, 20150115
1713458 28/2015 Austria See Plans and Pricing PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150119
1713458 216 5010-2015 Slovakia See Plans and Pricing PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978 20150119
1713458 C300742 Netherlands See Plans and Pricing PRODUCT NAME: OSPEMIFEEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/978 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Express Scripts
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.